The global non-injectable insulin market is estimated to be worth US$ 1.7 billion in 2024. From 2024 to 2034, the market is projected to grow at a solid clip, registering a CAGR of 13.5%.
| Attributes | Key Insights |
|---|---|
| Global Non-injectable Insulin Market Size (2024E) | US$ 1.7 billion |
| Market Value (2034F) | US$ 6.1 billion |
| Value-based CAGR (2024 to 2034) | 13.5% |
Growing prevalence of diabetes worldwide is surging the demand for non-injectable insulin as patients seek more comfort and convenience from the treatment. Cultural considerations and healthcare providers' willingness to try new treatments are set to impact patient preferences and adoption of non-injectable insulin.
In the pharmaceutical industry, the non-injectable insulin market provides easy and less challenging alternatives to traditional insulin injections, such as transdermal patches, oral insulin, and inhalable insulin. The market is growing due to innovative developments in drug delivery technology, which have resulted in more dependable and effective non-injectable insulin replacements.
Technological innovations in non-injectable insulin delivery devices are estimated to improve consumer experience and adherence, resulting in revenue growth and placing firms as competitive leaders. By 2034, the market is anticipated to reach US$ 6.1 billion.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2019 to 2023, the market has prolonged due to patient preferences for non-injectable products, fueled by advantages such as convenience, simplicity of administration, and less discomfort. The market grew at a CAGR of 17.0% between 2019 and 2023.
The advent of inhalable insulin was one of the prevalent changes in the non-injectable insulin industry. Exubera, the first inhalable insulin medication, received the United States Food & Drug Administration (FDA) approval in 2006. Afrezza's release, despite initial disappointment due to poor demand and concerns about its bulky inhaler, renewed interest in inhalable insulin, enhancing consumer acceptability.
The FDA's regulatory control, in particular, has had a key impact on the market. For non-injectable insulin solutions, strict regulatory criteria for safety, effectiveness, and quality standards have impacted clinical trial designs, product development, and market access. Although Afrezza is still the only FDA-approved inhaled insulin medication in the United States, several manufacturers have looked into creating comparable goods.
The demand for insulin is competitive. It is projected to spur innovation, enhance product offerings, and increase diabetes patients' treatment alternatives. By 2034, the market is set to surge at a CAGR of 13.5%, which is comparatively low from 2019 to 2023.
Insulin that is not injectable is now delivered more effectively because of developments in inhalation technology, including creating more accurate and effective inhaler devices. Sustained drug delivery methods, formulation optimization, and device design innovations are projected to boost market growth and enhance patient outcomes for non-injectable insulin treatment.
Leading companies are researching oral insulin formulations that can withstand digestive system conditions. They are potentially revolutionizing diabetes management by offering a comfortable, painless alternative to needles. Diabetes patients seek non-injectable insulin replacements due to needle phobia and daily hassles, pushing pharmaceutical companies to invest in unique products.
Regulatory bodies such as the FDA are evaluating and approving new insulin products, leading to a booming market. Pharmaceutical companies are collaborating with healthcare providers, IT companies, and research organizations to propel the development of insulin-delivery products.
Leading healthcare companies and professionals prioritize cost and accessibility to ensure all patients can access enhanced non-injectable solutions, fueling the market. The design process for insulin delivery systems is vital for diabetes patients, considering their preferences and input, thereby accelerating demand for non-injectable insulin.
Principal Consultant
The table below shows the estimated growth rates of the leading five nations. South Korea, Japan, and the United Kingdom are set to emerge as profitable markets for companies, recording CAGRs of 16.0%, 15.2%, and 14.6%, respectively, through 2034.
| Countries | Projected CAGR (2024 to 2034) |
|---|---|
| United States | 13.8% |
| United Kingdom | 14.6% |
| China | 14.2% |
| South Korea | 16.0% |
| Japan | 15.2% |
The table below highlights key countries’ market revenues. The United States and China are forecast to remain the leading consumers of non-injectable insulin, with predicted valuations of US$ 1.1 billion and US$ 1.0 billion, respectively, in 2034.
| Countries | Market Value (2034) |
|---|---|
| United States | US$ 1.1 billion |
| United Kingdom | US$ 243.2 million |
| China | US$ 1.0 billion |
| South Korea | US$ 395.6 million |
| Japan | US$ 665.7 million |
Japan's non-injectable insulin market is projected to reach a valuation of around US$ 665.7 million by 2034. Japan, with its high diabetes prevalence, urbanization, and growing healthcare infrastructure, is experiencing increased demand for innovative diabetes management solutions.
The growing awareness of insulin's convenience and reduced pain are projected to fuel the adoption of non-injectable insulin in Japan. Government initiatives and collaborations with pharmaceutical companies further promote market growth, positioning Japan as a leading player in the market.
The competitive landscape in Japan's pharmaceutical industry is projected to spur innovation and sales expansion in the non-injectable insulin market. Leading companies in Japan invest in research & development to enhance product formulas, delivery methods, and patient care services to set themselves apart.
Demand for non-injectable insulin is increasing in the United States, with a projected CAGR of 13.8% through 2034. MannKind Corporation's Afrezza is the primary insulin product for adults with diabetes, developed in the United States. It is a rapid-acting inhaled insulin available in powder form and regulated through an inhaler device.
Patient adoption and acceptability of non-injectable insulin treatments is determined by a number of factors, including cost, affordability, availability, efficacy, and safety. Campaigns for patient & healthcare professional education and awareness are planned to promote the benefits and increase adoption of non-injectable insulin therapy in the United States.
The non-injectable insulin market is projected to increase in South Korea at a CAGR of 16.0% through 2034. South Korea is anticipated to undergo research & development activities to improve pharmaceutical compositions, delivery systems, and patient outcomes, fueling demand for non-injectable insulin. Collaborations among pharmaceutical firms, healthcare providers, and regulatory bodies are vital for pouring innovation and increasing access to non-injectable insulin therapy in South Korea.
Pills stand atop the pile in the product type segment. The segment is anticipated to grow at a CAGR of 13.3% by 2034. Drug stores remain the predominant mode of distribution channel.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Pills (Product) | 13.3% |
| Drug Stores (Distribution Channel) | 13.1% |
Oral insulin tablets are projected to rise at 13.3% CAGR through 2034. The marketing and distribution of insulin pills is dependent on permission from health authorities such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). Oral medicines are projected to improve insulin therapy adherence in individuals who find injections uncomfortable or unpleasant.
In January 2023, for instance, researchers at the UiT Norway's Arctic University published a paper in Nature Nanotechnology. It states that out of the 425 million people suffering from diabetes across the globe, nearly 75 million inject themselves with insulin. However, this can soon change as researchers have found a novel method to supply smart insulin. It can be taken by the patient as a capsule or with any other food item, including chocolates.
Drug stores provide non-injectable medicines and specialized healthcare services, whereas specialty pharmacies focus on complicated medical conditions such as diabetes. Drug stores offer prescription counseling, adherence monitoring, and insurance help, making them important to ensure easy and convenient pharmaceutical access.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
A few leading companies and manufacturers dominate the market. They are launching new products worldwide to meet consumer demands and investing in research & development. Key companies also use several growth strategies to inflate their market reach and customer base, including mergers, acquisitions, partnerships, and collaborations.
For instance
The industry is set to reach a valuation of US$ 1.7 billion in 2024.
Demand for non-injectable insulin is set to rise at 13.5% CAGR by 2034.
The industry is projected to reach US$ 6.1 billion in 2034.
Novo Nordisk, Sanofi, and Eli Lilly are the key players.
The pills segment is estimated to hold a significant market share in 2024.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ million) & Volume (Units) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ million) & Volume (Units) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Product, 2019 to 2023 5.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Product, 2024 to 2034 5.3.1. Pills 5.3.2. Sprays 5.3.3. Others 5.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Distribution Channel, 2019 to 2023 6.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2024 to 2034 6.3.1. Hospital Pharmacies 6.3.2. Online Pharmacies 6.3.3. Drug Stores 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Region, 2019 to 2023 7.3. Current Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Region, 2024 to 2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 8.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 8.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 8.2.1. By Country 8.2.1.1. United States 8.2.1.2. Canada 8.2.2. By Product 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Product 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Product 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Product 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Product 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Product 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Product 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of Middle East and Africa 14.2.2. By Product 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. United States 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2024 15.1.2.1. By Product 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2024 15.2.2.1. By Product 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2024 15.3.2.1. By Product 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2024 15.4.2.1. By Product 15.4.2.2. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2024 15.5.2.1. By Product 15.5.2.2. By Distribution Channel 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2024 15.6.2.1. By Product 15.6.2.2. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2024 15.7.2.1. By Product 15.7.2.2. By Distribution Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2024 15.8.2.1. By Product 15.8.2.2. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2024 15.9.2.1. By Product 15.9.2.2. By Distribution Channel 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2024 15.10.2.1. By Product 15.10.2.2. By Distribution Channel 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2024 15.11.2.1. By Product 15.11.2.2. By Distribution Channel 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2024 15.12.2.1. By Product 15.12.2.2. By Distribution Channel 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2024 15.13.2.1. By Product 15.13.2.2. By Distribution Channel 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2024 15.14.2.1. By Product 15.14.2.2. By Distribution Channel 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2024 15.15.2.1. By Product 15.15.2.2. By Distribution Channel 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2024 15.16.2.1. By Product 15.16.2.2. By Distribution Channel 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2024 15.17.2.1. By Product 15.17.2.2. By Distribution Channel 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2024 15.18.2.1. By Product 15.18.2.2. By Distribution Channel 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2024 15.19.2.1. By Product 15.19.2.2. By Distribution Channel 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2024 15.20.2.1. By Product 15.20.2.2. By Distribution Channel 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2024 15.21.2.1. By Product 15.21.2.2. By Distribution Channel 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2024 15.22.2.1. By Product 15.22.2.2. By Distribution Channel 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2024 15.23.2.1. By Product 15.23.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Novo Nordisk 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Sanofi 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Eli Lilly 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. MannKind Corporation 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Biocon 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Janssen Pharmaceuticals 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Adocia 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Oramed Pharmaceuticals 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Dance Biopharm 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Medtronic 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 17.1.11. Verily Life Sciences 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.11.5.2. Product Strategy 17.1.11.5.3. Channel Strategy 17.1.12. Zafgen 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.12.5.2. Product Strategy 17.1.12.5.3. Channel Strategy 17.1.13. Dance Biopharm 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.13.5.2. Product Strategy 17.1.13.5.3. Channel Strategy 17.1.14. Senseonics 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 17.1.14.5.2. Product Strategy 17.1.14.5.3. Channel Strategy 17.1.15. Bigfoot Biomedical 17.1.15.1. Overview 17.1.15.2. Product Portfolio 17.1.15.3. Profitability by Market Segments 17.1.15.4. Sales Footprint 17.1.15.5. Strategy Overview 17.1.15.5.1. Marketing Strategy 17.1.15.5.2. Product Strategy 17.1.15.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Non-injectable Insulin Market
